Business Wire

Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/

Dr. Howard Mayer, Executive Vice-President and Head of Research and Development, effective December 1st, 2019 (Photo: Business Wire)

Dr. Howard Mayer, Executive Vice-President and Head of Research and Development, effective December 1st, 2019 (Photo: Business Wire)

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Dr. Howard Mayer as Executive Vice President and Head of Research and Development, effective December 1st, 2019. He succeeds Dr. Alexandre Lebeaut, Executive Vice President, Research and Development, Chief Scientific Officer, who will retire from the company at the end of the year. Based in Cambridge, Mass, U.S., Dr. Mayer will report directly to David Meek, CEO, Ipsen and serve on the Executive Leadership Team.

David Meek, CEO, Ipsen, commented, “As Ipsen enters its next phase of growth, it is my great pleasure to appoint Dr. Mayer to lead Ipsen’s R&D organization. He brings a wealth of outstanding clinical, medical and leadership experience from a number of global biopharmaceutical companies. Ipsen’s pipeline has never been as rich as it is today, with six Phase 3 or registration trials scheduled for 2020. Dr. Mayer will play a pivotal role in driving our R&D strategy to further grow our pipeline and build a truly differentiated and sustainable portfolio across our key areas of expertise. He will lead the development of innovative therapeutic solutions for our Oncology and Neuroscience franchises including Systemic Radiation Therapy (SRT), while building on our leadership position in neurotoxin research. With extensive experience in rare diseases, Dr. Mayer will also advance our fast-growing Rare Diseases portfolio.”

In his role, Dr. Mayer will work closely with Ipsen’s Business Development team to assess and execute on in-licensing or out-licensing opportunities and build internal expertise accordingly. He will also contribute to the overall management and strategic leadership of the company as a member of the Executive Leadership team. Recognized as an exceptional team leader, Dr. Mayer will be responsible for building a culture centered on collaboration, agility and partnership. By doing so, he will fulfill the company’s vision as a leading global biopharmaceutical company focused on innovation and Specialty Care.

Prior to joining Ipsen, Dr. Mayer was Senior Vice President, Chief Medical Officer and Head of Research and Development, Neuroscience Division, Shire Pharmaceuticals. Dr. Mayer has held several global leadership positions in clinical development and medical affairs with biopharmaceutical companies including EMD Serono, Pfizer and Bristol-Myers Squibb. He obtained his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School.

About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.fr

Ipsen—Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2018 Registration Document available on its website (www.ipsen.com).

Contact information

Media
Christian Marcoux
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Christian.marcoux@ipsen.com

Fanny Allaire
Director, Ipsen France Hub, Global Communications
+33 (0) 1 58 33 58 96
Fanny.allaire@ipsen.com

Financial Community
Eugenia Litz
Vice President, Investor Relations
+44 (0) 1753 627721
eugenia.litz@ipsen.com

Myriam Koutchinsky
Investor Relations Manager
+33 (0)1 58 33 51 04
myriam.koutchinsky@ipsen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AskNicely Opens Amsterdam Office To Meet Growing Demand in Europe22.1.2020 23:05:00 EETPress release

AskNicely, the customer experience platform for people-powered businesses, today announced the opening of its first European office in Amsterdam. The company is headquartered in Portland, Oregon and recently expanded its original office in Auckland, New Zealand. “Amsterdam has become a hub for innovation,” said AskNicely co-founder and CEO Aaron Ward. “We recognize the potential of the city’s incredible talent pool, its world-class infrastructure, and the vibrant growth that has fueled the Amsterdam tech scene.” The European office was added in response to customer demand, and to accelerate the company’s growth plans. In 2019, AskNicely raised $10 million in Series A funding and expanded on its core NPS software by launching the world’s first mobile customer experience coaching app, which helps companies consistently deliver on their brand promise by using real-time feedback to coach employees. “I am delighted that AskNicely has chosen to set up its operations in the Netherlands and ho

Strong Revenue Growth in 2019 and Promising Outlook22.1.2020 19:45:00 EETPress release

Kalray (Paris:ALKAL) (Euronext Growth Paris : ALKAL), a pioneer in processors for new intelligent systems, reviews its business in the second half of 2019 (from July 1 to December 31, 2019) and looks back over the highlights of the period. Eric Baissus, President of Kalray’s Executive Board, commented as follows: “2019 was a pivotal year for Kalray marked by the achievement of a number of key milestones. First of all, we finished developing our 3rd generation Coolidge™ processor and presented it for the first time in early January at CES. Mass production is scheduled to start second semester of 2020. Furthermore, strategic agreements were signed with top-tier players including NXP, Wistron, 2CRSI and Intron Technology, which will boost our credibility and accelerate time to market for Coolidge™. Our target of achieving revenues of €100 million by 2022 have been confirmed by the initial performances of Coolidge™, the industry enthusiasm which we were able to measure at CES and the numer

PMI Salary Survey Reveals Project Management Practitioners with the PMP Certification Earn 22% More22.1.2020 19:30:00 EETPress release

The Project Management Institute (PMI) today released its “Earning Power: Project Management Salary Survey” which reveals a significant advantage in earning potential for practitioners who hold the Project Management Professional (PMP)® certification. According to the survey, respondents with a PMP certification reported higher median salaries than those without a PMP certification -- 22% higher on average across the 42 countries surveyed. New in this edition is salary information from five countries not previously covered— Indonesia, Pakistan, the Philippines, Portugal and the Russian Federation. The 11th edition of the survey incorporates information from more than 32,000 project management practitioners in 42 countries across the globe. The comprehensive biennial survey offers insight into the value of project management skills, experience and certifications. It is an industry-leading source of data, giving project management practitioners a greater awareness of their earning potent

Philip Morris International Wins 2020 BIG Innovation Award22.1.2020 18:05:00 EETPress release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that it has won the 2020 BIG Innovation Award in the “Organization” category. The company was honored for placing innovation front and center as it continues its full-scale business transformation to deliver a smoke-free future and replace cigarettes with better alternatives for those adults who would otherwise continue to smoke. The BIG Innovation Awards, presented by the Business Intelligence Group, recognize organizations, products and people who bring new ideas to life. Organizations from across the globe submitted their recent innovations for consideration, and nominations were judged by a select group of business leaders and executives. “It is gratifying to continue to be recognized by the broader business community for the innovation that is fueling our progress toward a smoke-free future,” said Jacek Olczak, PMI’s chief operating officer. “As we are undergoing the largest transformation in our company’s history,

Sevan Refreshes 14,000th Restaurant22.1.2020 17:00:00 EETPress release

Sevan Multi-Site Solutions, Inc. (Sevan)—a global leader in innovative design, program management, construction services and data analytics—just finished refreshing their 14,000th restaurant. For eight years, Sevan has provided solutions for the world’s largest brands while accelerating development programs across the United States and Canada for multi-site clients. Sevan has partnered on restaurant programs with Carl’s Jr., Carrols Corporation (a Burger King franchisee), Chipotle, McDonald’s, Panera, Starbucks, Taco Bell, Army & Air Force Exchange Service (Exchange) restaurants and others. Sevan’s Chief Revenue Officer Jim Furis says working with great clients is the best part of the company’s success in the Quick Service Restaurant (QSR) world. “Each client is unique and their project execution style varies widely. Not surprisingly, they all share one objective—to deliver a fantastic customer experience in a reliable way at loads of locations,” Furis said. “Sevan is proud to have pla

Mary Kay Inc. Celebrates Milestone Anniversaries Around the World22.1.2020 16:50:00 EETPress release

Blow out the pink candles and make a wish—in 2020, Mary Kay Inc. will celebrate milestone anniversaries in some of its most important markets around the globe. The iconic Mary Kay Ash, with humble roots in small town, Texas, founded her namesake brand in 1963. The brand quickly developed into a worldwide phenomenon with millions of independent beauty consultants in nearly 40 countries. While beauty trends come and go, Mary Kay owes its staying power to something that never goes out of style: female empowerment and a greater purpose to do good. “While our innovative skin care, on-trend color cosmetics, fragrances and body care products have been loved for more than 56 years by millions of consumers around the world, our company was founded with much more than lipstick in mind,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “Our founder, Mary Kay Ash, built her dream company with two goals: create economic independence for women through entrepreneurship, and make the world a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom